{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:10:38Z","timestamp":1778155838432,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2022F5N25M"],"award-info":[{"award-number":["2022F5N25M"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"DOI":"10.1007\/s12026-026-09783-1","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:17:37Z","timestamp":1778152657000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fine specificity of antibodies to SARS-CoV-2 nucleoprotein in patients with COVID-19"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6771-4361","authenticated-orcid":false,"given":"Caterina","family":"Porciani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8305-8976","authenticated-orcid":false,"given":"Francesco","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9274-2313","authenticated-orcid":false,"given":"Maria Laura","family":"Manca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0737-2213","authenticated-orcid":false,"given":"Lorenzo","family":"Pacini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7790-9886","authenticated-orcid":false,"given":"Fosca","family":"Errante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Mozzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6433-4964","authenticated-orcid":false,"given":"Paola","family":"Migliorini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7226-0907","authenticated-orcid":false,"given":"Federico","family":"Pratesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"1","key":"9783_CR1","doi-asserted-by":"publisher","first-page":"13417","DOI":"10.1038\/s41598-024-64414-9","volume":"14","author":"M Movsisyan","year":"2024","unstructured":"Movsisyan M, Truzyan N, Kasparova I, et al. Tracking the evolution of anti-SARS-CoV-2 antibodies and long-term humoral immunity within 2 years after COVID-19 infection. Sci Rep. 2024;14(1):13417. https:\/\/doi.org\/10.1038\/s41598-024-64414-9.","journal-title":"Sci Rep"},{"issue":"4","key":"9783_CR2","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","volume":"183","author":"L Piccoli","year":"2020","unstructured":"Piccoli L, Park YJ, Tortorici MA, et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell. 2020;183(4):1024\u2013e104221. https:\/\/doi.org\/10.1016\/j.cell.2020.09.037.","journal-title":"Cell"},{"issue":"3","key":"9783_CR3","doi-asserted-by":"publisher","first-page":"e01828","DOI":"10.1128\/JVI.01828-20","volume":"95","author":"C Fenwick","year":"2021","unstructured":"Fenwick C, Croxatto A, Coste AT, et al. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. J Virol. 2021;95(3):e01828\u201320. https:\/\/doi.org\/10.1128\/JVI.01828-20.","journal-title":"J Virol"},{"issue":"1","key":"9783_CR4","doi-asserted-by":"publisher","first-page":"6044","DOI":"10.1038\/s41467-020-19943-y","volume":"11","author":"K Li","year":"2020","unstructured":"Li K, Huang B, Wu M, et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nat Commun. 2020;11(1):6044. https:\/\/doi.org\/10.1038\/s41467-020-19943-y.","journal-title":"Nat Commun"},{"issue":"4","key":"9783_CR5","doi-asserted-by":"publisher","first-page":"100041","DOI":"10.1016\/j.jcvp.2021.100041","volume":"1","author":"B Crescenzo-Chaigne","year":"2021","unstructured":"Crescenzo-Chaigne B, Behillil S, et al. French COVID cohort study group. Nasopharyngeal and serological anti SARS-CoV-2 IgG\/IgA responses in COVID-19 patients. J Clin Virol Plus. 2021;1(4):100041. https:\/\/doi.org\/10.1016\/j.jcvp.2021.100041.","journal-title":"J Clin Virol Plus"},{"issue":"6","key":"9783_CR6","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.immuni.2021.05.001","volume":"54","author":"HL Dugan","year":"2021","unstructured":"Dugan HL, Stamper CT, Li L, et al. Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity. 2021;54(6):1290\u2013e13037. https:\/\/doi.org\/10.1016\/j.immuni.2021.05.001.","journal-title":"Immunity"},{"issue":"5","key":"9783_CR7","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.immuni.2021.04.006","volume":"54","author":"KE Lineburg","year":"2021","unstructured":"Lineburg KE, Grant EJ, Swaminathan S, et al. CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses. Immunity. 2021;54(5):1055\u2013e10655. https:\/\/doi.org\/10.1016\/j.immuni.2021.04.006.","journal-title":"Immunity"},{"issue":"17","key":"9783_CR8","doi-asserted-by":"publisher","first-page":"e108588","DOI":"10.15252\/embj.2021108588","volume":"40","author":"A Albecka","year":"2021","unstructured":"Albecka A, Clift D, Vaysburd M, et al. A functional assay for serum detection of antibodies against SARS-CoV-2 nucleoprotein. EMBO J. 2021;40(17):e108588. https:\/\/doi.org\/10.15252\/embj.2021108588.","journal-title":"EMBO J"},{"issue":"1","key":"9783_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-12032-8","volume":"12","author":"A Facciuolo","year":"2022","unstructured":"Facciuolo A, Scruten E, Lipsit S, et al. High-resolution analysis of long-term serum antibodies in humans following convalescence of SARS-CoV-2 infection. Sci Rep. 2022;12(1):9045. https:\/\/doi.org\/10.1038\/s41598-022-12032-8.","journal-title":"Sci Rep"},{"key":"9783_CR10","doi-asserted-by":"publisher","unstructured":"Shrock E, Fujimura E, Kula T, MGH COVID-19 Collection & Processing Team, Villani AC, Kays K, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science. 2020;370(6520):eabd4250. https:\/\/doi.org\/10.1126\/science.abd4250.","DOI":"10.1126\/science.abd4250"},{"issue":"1","key":"9783_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/femspd\/ftac001","volume":"80","author":"F Maghsood","year":"2022","unstructured":"Maghsood F, Shokri MR, Jeddi-Tehrani M, et al. Identification of immunodominant epitopes on nucleocapsid and spike proteins of the SARS-CoV-2 in Iranian COVID-19 patients. Pathog Dis. 2022;80(1):ftac001. https:\/\/doi.org\/10.1093\/femspd\/ftac001.","journal-title":"Pathog Dis"},{"issue":"W1","key":"9783_CR12","doi-asserted-by":"publisher","first-page":"W24","DOI":"10.1093\/nar\/gkx346","volume":"45","author":"MC Jespersen","year":"2017","unstructured":"Jespersen MC, Peters B, Nielsen M, Marcatili P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res. 2017;45(W1):W24\u20139. https:\/\/doi.org\/10.1093\/nar\/gkx346.","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"9783_CR13","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/psc.1395","volume":"17","author":"F Rizzolo","year":"2011","unstructured":"Rizzolo F, Testa C, Lambardi D, et al. Conventional and microwave-assisted SPPS approach: a comparative synthesis of PTHrP(1\u201334)NH(2). J Pept Sci. 2011;17(10):708\u201314. https:\/\/doi.org\/10.1002\/psc.1395.","journal-title":"J Pept Sci"},{"issue":"6","key":"9783_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9060672","volume":"9","author":"F Pratesi","year":"2021","unstructured":"Pratesi F, Caruso T, Testa D, et al. BNT162b2 mRNA SARS-CoV-2 vaccine elicits high avidity and neutralizing antibodies in healthcare workers. Vaccines. 2021;9(6):672. https:\/\/doi.org\/10.3390\/vaccines9060672.","journal-title":"Vaccines"},{"issue":"1\u20132","key":"9783_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jim.2012.09.008","volume":"387","author":"G Almanzar","year":"2013","unstructured":"Almanzar G, Ottensmeier B, Liese J, Prelog M. Assessment of IgG avidity against pertussis toxin and filamentous hemagglutinin via an adapted enzyme-linked immunosorbent assay (ELISA) using ammonium thiocyanate. J Immunol Methods. 2013;387(1\u20132):36\u201342. https:\/\/doi.org\/10.1016\/j.jim.2012.09.008.","journal-title":"J Immunol Methods"},{"issue":"9","key":"9783_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/v17091168","volume":"17","author":"DM Mateescu","year":"2025","unstructured":"Mateescu DM, Ilie AC, Cotet I, et al. Predicting COVID-19 sepsis outcomes: roles of IL-6, cardiac biomarkers, clinical factors, and vaccination status and exploratory analysis of tocilizumab therapy in an Eastern European cohort. Viruses. 2025;17(9):1168. https:\/\/doi.org\/10.3390\/v17091168.","journal-title":"Viruses"},{"key":"9783_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12026-021-09198-0","volume":"69","author":"R Lotfi","year":"2021","unstructured":"Lotfi R, Kalmarzi RN, Roghani SA. A review on the immune responses against novel emerging coronavirus (SARS-CoV-2). Immunol Res. 2021;69:213\u201324. https:\/\/doi.org\/10.1007\/s12026-021-09198-0.","journal-title":"Immunol Res"},{"issue":"5","key":"9783_CR18","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1021\/cc0500607","volume":"7","author":"H Hu","year":"2005","unstructured":"Hu H, Li L, Kao RY, et al. Screening and identification of linear B-cell epitopes and entry-blocking peptide of Severe Acute Respiratory Syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library. J Comb Chem. 2005;7(5):648\u201356. https:\/\/doi.org\/10.1021\/cc0500607.","journal-title":"J Comb Chem"},{"issue":"12","key":"9783_CR19","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1373\/clinchem.2003.023184","volume":"49","author":"J Wang","year":"2003","unstructured":"Wang J, Wen J, Li J, et al. Assessment of immunoreactive synthetic peptides from the structural proteins of Severe Acute Respiratory Syndrome coronavirus. Clin Chem. 2003;49(12):1989\u201396. https:\/\/doi.org\/10.1373\/clinchem.2003.023184.","journal-title":"Clin Chem"},{"issue":"3","key":"9783_CR20","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00324-23","volume":"11","author":"JP Vandervaart","year":"2023","unstructured":"Vandervaart JP, Inniss NL, Ling-Hu T, et al. Serodominant SARS-CoV-2 nucleocapsid peptides map to unstructured protein regions. Microbiol Spectr. 2023;11(3):e0032423. https:\/\/doi.org\/10.1128\/spectrum.00324-23.","journal-title":"Microbiol Spectr"},{"issue":"6","key":"9783_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23062977","volume":"23","author":"A Tajuelo","year":"2022","unstructured":"Tajuelo A, L\u00f3pez-Siles M, M\u00e1s V, et al. Cross-recognition of SARS-CoV-2 B-Cell epitopes with other betacoronavirus nucleoproteins. Int J Mol Sci. 2022;23(6):2977. https:\/\/doi.org\/10.3390\/ijms23062977.","journal-title":"Int J Mol Sci"},{"key":"9783_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijid.2021.01.061","volume":"106","author":"G Bauer","year":"2021","unstructured":"Bauer G. The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2. Int J Infect Dis. 2021;106:61\u20134. https:\/\/doi.org\/10.1016\/j.ijid.2021.01.061.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"9783_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-023-02310-4","volume":"28","author":"T Caruso","year":"2023","unstructured":"Caruso T, Salani F, Catanese S, et al. Correction to: repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies. Int J Clin Oncol. 2023;28(3):370. https:\/\/doi.org\/10.1007\/s10147-023-02310-4.","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"9783_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/v14071491","volume":"14","author":"L Garcia","year":"2022","unstructured":"Garcia L, Woudenberg T, Rosado J, et al. Kinetics of the SARS-CoV-2 antibody avidity response following infection and vaccination. Viruses. 2022;14(7):1491. https:\/\/doi.org\/10.3390\/v14071491.","journal-title":"Viruses"},{"issue":"12","key":"9783_CR25","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1093\/infdis\/jiaa581","volume":"222","author":"SE Benner","year":"2020","unstructured":"Benner SE, Patel EU, Laeyendecker O, et al. SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors. J Infect Dis. 2020;222(12):1974\u201384. https:\/\/doi.org\/10.1093\/infdis\/jiaa581.","journal-title":"J Infect Dis"},{"issue":"3","key":"9783_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00430-023-00763-y","volume":"212","author":"M Hajilooi","year":"2023","unstructured":"Hajilooi M, Keramat F, Moazenian A, et al. The quantity and quality of anti-SARS-CoV-2 antibodies show contrariwise association with COVID-19 severity: lessons learned from IgG avidity. Med Microbiol Immunol. 2023;212(3):203\u201320. https:\/\/doi.org\/10.1007\/s00430-023-00763-y.","journal-title":"Med Microbiol Immunol"},{"issue":"9","key":"9783_CR27","doi-asserted-by":"publisher","first-page":"5409","DOI":"10.1002\/jmv.27058","volume":"93","author":"FN Zervou","year":"2021","unstructured":"Zervou FN, Louie P, Stachel A, et al. SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection. J Med Virol. 2021;93(9):5409\u201315. https:\/\/doi.org\/10.1002\/jmv.27058.","journal-title":"J Med Virol"},{"issue":"1","key":"9783_CR28","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s42003-025-09034-3","volume":"8","author":"N Pedre\u00f1o-L\u00f3pez","year":"2025","unstructured":"Pedre\u00f1o-L\u00f3pez N, Tarr\u00e9s-Freixas F, Usai C, et al. Anti-SARS-CoV-2 antibodies from severe COVID-19 individuals or S2 immunizations do not worsen disease in hamsters. Commun Biol. 2025;8(1):1643. https:\/\/doi.org\/10.1038\/s42003-025-09034-3.","journal-title":"Commun Biol"},{"issue":"6","key":"9783_CR29","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1515\/cclm-2023-1487","volume":"62","author":"S Mink","year":"2024","unstructured":"Mink S, Reimann P, Fraunberger P. Prognostic value of anti-SARS-CoV-2 antibodies: a systematic review. Clin Chem Lab Med. 2024;62(6):1029\u201343. https:\/\/doi.org\/10.1515\/cclm-2023-1487.","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"9783_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1684\/ecn.2020.0448","volume":"31","author":"H Mojtabavi","year":"2020","unstructured":"Mojtabavi H, Saghazadeh A, Rezaei N. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis. Eur Cytokine Netw. 2020;31(2):44\u20139. https:\/\/doi.org\/10.1684\/ecn.2020.0448. PMID: 32933891; PMCID: PMC7530350.","journal-title":"Eur Cytokine Netw"},{"issue":"1","key":"9783_CR31","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/s41467-022-28621-0","volume":"13","author":"YM Mueller","year":"2022","unstructured":"Mueller YM, Schrama TJ, Ruijten R, et al. Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning. Nat Commun. 2022;13(1):915. https:\/\/doi.org\/10.1038\/s41467-022-28621-0.","journal-title":"Nat Commun"},{"key":"9783_CR32","doi-asserted-by":"publisher","first-page":"835830","DOI":"10.3389\/fimmu.2022.835830","volume":"13","author":"E Taus","year":"2022","unstructured":"Taus E, Hofmann C, Ibarrondo FJ, et al. Dominant CD8+ T Cell Nucleocapsid Targeting in SARS-CoV-2 Infection and Broad Spike Targeting From Vaccination. Front Immunol. 2022;13:835830. https:\/\/doi.org\/10.3389\/fimmu.2022.835830.","journal-title":"Front Immunol"},{"issue":"3","key":"9783_CR33","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/cei.13627","volume":"205","author":"J Verhagen","year":"2021","unstructured":"Verhagen J, van der Meijden ED, Lang V, et al. Human CD4+T cells specific for dominant epitopes of SARS-CoV-2 spike and nucleocapsid proteins with therapeutic potential. Clin Exp Immunol. 2021;205(3):363\u201378. https:\/\/doi.org\/10.1111\/cei.13627.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"9783_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32547-y","volume":"13","author":"JT Castro","year":"2022","unstructured":"Castro JT, Azevedo P, Fumagalli MJ, et al. Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-nucleocapsid fusion protein. Nat Commun. 2022;13(1):4831. https:\/\/doi.org\/10.1038\/s41467-022-32547-y.","journal-title":"Nat Commun"},{"issue":"7","key":"9783_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110177","volume":"27","author":"BVS Valiate","year":"2024","unstructured":"Valiate BVS, Castro JT, Mar\u00e7al TG, et al. Evaluation of an RBD-nucleocapsid fusion protein as a booster candidate for COVID-19 vaccine. iScience. 2024;27(7):110177. https:\/\/doi.org\/10.1016\/j.isci.2024.110177.","journal-title":"iScience"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09783-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-026-09783-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09783-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:17:38Z","timestamp":1778152658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-026-09783-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9783"],"URL":"https:\/\/doi.org\/10.1007\/s12026-026-09783-1","relation":{},"ISSN":["1559-0755"],"issn-type":[{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The procedures used in this study adhere to the tenets of the Declaration of Helsinki. The study was approved by the Area Vasta Nord Ovest Ethic Committee (CEAVNO \u2013 approval number 17522\/2020). Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial number"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}